Byrne Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Byrne Lee has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Mark Wakabayashi
Department of Surgery, City of Hope National Medical Center, Duarte, California
4 shared publicationsSinziana Dumitra
Department of Surgery, City of Hope National Medical Center, Duarte, California
4 shared publicationsI. Benjamin Paz
Department of Surgery, City of Hope National Medical Center , Duarte, California
3 shared publicationsMustafa Raoof
Department of Surgery, City of Hope National Cancer Center, Medical Office Building, 1500 Duarte Road, Duarte, CA, USA
3 shared publicationsOliver S. Eng
Department of Surgery, City of Hope National Medical Center , Duarte, California
3 shared publicationsClayton Lau
Department of Surgery, City of Hope National Cancer Center, Medical Office Building, 1500 Duarte Road, Duarte, CA, USA
2 shared publications
Latest Publications
- Open Access
- 10 March 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (3) , 748
Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review
Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with improved survival for patients with colorectal peritoneal metastases (CR-PM). However, the role of neoadjuvant chemotherapy (NAC) prior to CRS-HIPEC is poorly understood. A retrospective review of adult patients with CR-PM who underwent CRS+/-HIPEC from 2000–2017 was performed. Among 298 patients who underwent CRS+/-HIPEC, 196 (65.8%) received NAC while 102 (34.2%) underwent surgery first (SF). Patients who received NAC had lower peritoneal cancer index score (12.1 + 7.9 vs. 14.3 + 8.5, p = 0.034). There was no significant difference in grade III/IV complications (22.4% vs. 16.7%, p = 0.650), readmission (32.3% vs. 23.5%, p = 0.114), or 30-day mortality (1.5% vs. 2.9%, p = 0.411) between groups. NAC patients experienced longer overall survival (OS) (median 32.7 vs. 22.0 months, p = 0.044) but similar recurrence-free survival (RFS) (median 13.8 vs. 13.0 months, p = 0.456). After controlling for confounding factors, NAC was not independently associated with improved OS (OR 0.80) or RFS (OR 1.04). Among patients who underwent CRS+/-HIPEC for CR-PM, the use of NAC was associated with improved OS that did not persist on multivariable analysis. However, NAC prior to CRS+/-HIPEC was a safe and feasible strategy for CR-PM, which may aid in the appropriate selection of patients for aggressive cytoreductive surgery.
- 10 March 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (3) , 748
Open AccessImpact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review
Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with improved survival for patients with colorectal peritoneal metastases (CR-PM). However, the role of neoadjuvant chemotherapy (NAC) prior to CRS-HIPEC is poorly understood. A retrospective review of adult patients with CR-PM who underwent CRS+/-HIPEC from 2000–2017 was performed. Among 298 patients who underwent CRS+/-HIPEC, 196 (65.8%) received NAC while 102 (34.2%) underwent surgery first (SF). Patients who received NAC had lower peritoneal cancer index score (12.1 + 7.9 vs. 14.3 + 8.5, p = 0.034). There was no significant difference in grade III/IV complications (22.4% vs. 16.7%, p = 0.650), readmission (32.3% vs. 23.5%, p = 0.114), or 30-day mortality (1.5% vs. 2.9%, p = 0.411) between groups. NAC patients experienced longer overall survival (OS) (median 32.7 vs. 22.0 months, p = 0.044) but similar recurrence-free survival (RFS) (median 13.8 vs. 13.0 months, p = 0.456). After controlling for confounding factors, NAC was not independently associated with improved OS (OR 0.80) or RFS (OR 1.04). Among patients who underwent CRS+/-HIPEC for CR-PM, the use of NAC was associated with improved OS that did not persist on multivariable analysis. However, NAC prior to CRS+/-HIPEC was a safe and feasible strategy for CR-PM, which may aid in the appropriate selection of patients for aggressive cytoreductive surgery.
- 11 December 2019
- Published by Springer Nature
- p. 179-188
Complications of Cytoreductive Surgery and HIPEC
- 11 December 2019
- Published by Springer Nature
- p. 179-188
Complications of Cytoreductive Surgery and HIPEC
- 6 September 2019
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 14 (3) , 503-507
Multivisceral robotic liver surgery: feasible and safe
The application of robotic technology allows for the performance of multi-organ liver resections by multidisciplinary teams in a minimally invasive manner. Their technique and outcomes are not established. Herein we describe our technique with robotic liver surgery combined with colon, pancreas and urologic resections. Our patients are an 84-year-old (yo) female (Body Mass Index, BMI: 25) with a recently diagnosed right colon adenocarcinoma and two synchronous liver metastases at segments 5 and 6, a 75-year-old female (BMI: 50.4) with a history of right renal cell cancer status post (s/p) right robotic radical nephrectomy now with tumor recurrence with multiple intra-abdominal masses including a segment 7 liver lesion and a 71-year-old female (BMI: 24) with history of pancreatic ductal adenocarcinoma of the tail and a segment 3 liver lesion s/p neoadjuvant chemotherapy. The Xi robotic system (Intuitive Surgical, Sunnyvale, CA, USA) was utilized in all cases. Port placement in all cases was decided within the multidisciplinary teams to accommodate both the hepatic and the extra-hepatic portion of the operation. Parenchymal transections were performed with the use of the Vessel Sealer and the robotic stapler as appropriate. Indocyanine green (ICG) was used to assess the anastomotic perfusion in the first patient. Blood loss was 50 ml for the first two cases and 300 ml for the third. Surgical margins were negative in all cases. Patients were discharged at POD 8, 3 and 5 with one patient experiencing postoperative ileus. Robotic multivisceral liver resections are feasible and safe within multidisciplinary surgical teams with expertise in robotic surgery. The robotic platform can offer a minimally invasive approach in liver surgery synchronous with colonic, pancreatic and urologic surgery.
- 6 September 2019
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 14 (3) , 503-507
Multivisceral robotic liver surgery: feasible and safe
The application of robotic technology allows for the performance of multi-organ liver resections by multidisciplinary teams in a minimally invasive manner. Their technique and outcomes are not established. Herein we describe our technique with robotic liver surgery combined with colon, pancreas and urologic resections. Our patients are an 84-year-old (yo) female (Body Mass Index, BMI: 25) with a recently diagnosed right colon adenocarcinoma and two synchronous liver metastases at segments 5 and 6, a 75-year-old female (BMI: 50.4) with a history of right renal cell cancer status post (s/p) right robotic radical nephrectomy now with tumor recurrence with multiple intra-abdominal masses including a segment 7 liver lesion and a 71-year-old female (BMI: 24) with history of pancreatic ductal adenocarcinoma of the tail and a segment 3 liver lesion s/p neoadjuvant chemotherapy. The Xi robotic system (Intuitive Surgical, Sunnyvale, CA, USA) was utilized in all cases. Port placement in all cases was decided within the multidisciplinary teams to accommodate both the hepatic and the extra-hepatic portion of the operation. Parenchymal transections were performed with the use of the Vessel Sealer and the robotic stapler as appropriate. Indocyanine green (ICG) was used to assess the anastomotic perfusion in the first patient. Blood loss was 50 ml for the first two cases and 300 ml for the third. Surgical margins were negative in all cases. Patients were discharged at POD 8, 3 and 5 with one patient experiencing postoperative ileus. Robotic multivisceral liver resections are feasible and safe within multidisciplinary surgical teams with expertise in robotic surgery. The robotic platform can offer a minimally invasive approach in liver surgery synchronous with colonic, pancreatic and urologic surgery.
- 1 August 2018
- Published by SAGE Publications in Surgical Infections
- Vol. 19 (6) , 618-621
Hypothermia Is Associated with Surgical Site Infection in Cytoreductive Surgery with Hyperthermic Intra-Peritoneal Chemotherapy
Background: Maintenance of peri-operative normothermia remains a global quality metric for hospitals. Hypothermia is associated with surgical site infections (SSIs) in colorectal surgery. Patients undergoing cytoreductive surgery (CRS) with hyperthermic intra-peritoneal chemotherapy (HIPEC) can experience multiple complications post-operatively. We sought to investigate the association of peri-operative hypothermia with SSIs in patients undergoing CRS/HIPEC at our institution. Patients and Methods: Patients undergoing CRS/HIPEC from 2009–2017 were identified retrospectively from a prospectively collected institutional database. Hypothermia defined as less than 36.0°C in accordance with the Agency for Healthcare Research and Quality metric. Regression analyses were performed with SSIs diagnosed within 30 days post-operatively as the primary outcome. Results: A total of 170 patients were identified, 14 (8.2%) of whom developed an SSI. Patients who developed an SSI experienced lower median temperatures (p = 0.027) and a greater percentage of operative time in hypothermia (p = 0.008). On a multivariable analysis adjusting for known risk factors for SSI, the percentage of operative time in hypothermia (odds ratio [OR] 1.04, 95% confidence interval [CI] 1.01–1.07, p = 0.008) was the only parameter associated with SSI within 30 days post-operatively. Conclusion: Hypothermia is associated with the development of SSIs in patients undergoing CRS/HIPEC. Our findings suggest that minimizing peri-operative temperatures to less than 36.0°C may decrease peri-operative SSI in this patient population.
- 1 August 2018
- Published by SAGE Publications in Surgical Infections
- Vol. 19 (6) , 618-621
Hypothermia Is Associated with Surgical Site Infection in Cytoreductive Surgery with Hyperthermic Intra-Peritoneal Chemotherapy
Background: Maintenance of peri-operative normothermia remains a global quality metric for hospitals. Hypothermia is associated with surgical site infections (SSIs) in colorectal surgery. Patients undergoing cytoreductive surgery (CRS) with hyperthermic intra-peritoneal chemotherapy (HIPEC) can experience multiple complications post-operatively. We sought to investigate the association of peri-operative hypothermia with SSIs in patients undergoing CRS/HIPEC at our institution. Patients and Methods: Patients undergoing CRS/HIPEC from 2009–2017 were identified retrospectively from a prospectively collected institutional database. Hypothermia defined as less than 36.0°C in accordance with the Agency for Healthcare Research and Quality metric. Regression analyses were performed with SSIs diagnosed within 30 days post-operatively as the primary outcome. Results: A total of 170 patients were identified, 14 (8.2%) of whom developed an SSI. Patients who developed an SSI experienced lower median temperatures (p = 0.027) and a greater percentage of operative time in hypothermia (p = 0.008). On a multivariable analysis adjusting for known risk factors for SSI, the percentage of operative time in hypothermia (odds ratio [OR] 1.04, 95% confidence interval [CI] 1.01–1.07, p = 0.008) was the only parameter associated with SSI within 30 days post-operatively. Conclusion: Hypothermia is associated with the development of SSIs in patients undergoing CRS/HIPEC. Our findings suggest that minimizing peri-operative temperatures to less than 36.0°C may decrease peri-operative SSI in this patient population.
- Open Access
- 1 December 2017
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 152 (12) , 1156-1160
Association of Fluid Administration With Morbidity in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as an important treatment modality for both primary and secondary peritoneal surface cancers. The CRS/HIPEC treatment involves peritonectomy procedures that often are accompanied by visceral organ resections and intestinal anastomoses, followed by perfusion of chemotherapy at 42°C.1,2 Even at high-volume centers, CRS/HIPEC can be associated with major morbidity in greater than 50% of patients across a variety of organ systems.3 This morbidity is multifactorial, as it is affected by patient demographics, tumor biology, and extent of treatment.3,4
- 1 December 2017
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 152 (12) , 1156-1160
Open AccessAssociation of Fluid Administration With Morbidity in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as an important treatment modality for both primary and secondary peritoneal surface cancers. The CRS/HIPEC treatment involves peritonectomy procedures that often are accompanied by visceral organ resections and intestinal anastomoses, followed by perfusion of chemotherapy at 42°C.1,2 Even at high-volume centers, CRS/HIPEC can be associated with major morbidity in greater than 50% of patients across a variety of organ systems.3 This morbidity is multifactorial, as it is affected by patient demographics, tumor biology, and extent of treatment.3,4
- 14 August 2017
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 24 (11) , 3422-3423
Robotic Total Pelvic Exenteration: Video-Illustrated Technique
Robotic-assisted total pelvic exenteration (TPE) can offer a minimally invasive approach to a major multi-organ operation.
- 14 August 2017
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 24 (11) , 3422-3423
Robotic Total Pelvic Exenteration: Video-Illustrated Technique
Robotic-assisted total pelvic exenteration (TPE) can offer a minimally invasive approach to a major multi-organ operation.
- 30 May 2017
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 24 (9) , 2707-2711
Base Excess as a Predictor of Complications in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
Base excess is important in assessing metabolic status. Postoperative management in patients undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies can be a challenge, and we therefore sought to investigate perioperative predictors of overall morbidity in CRS/HIPEC patients at our institution.
- 30 May 2017
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 24 (9) , 2707-2711
Base Excess as a Predictor of Complications in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
Base excess is important in assessing metabolic status. Postoperative management in patients undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies can be a challenge, and we therefore sought to investigate perioperative predictors of overall morbidity in CRS/HIPEC patients at our institution.
- Open Access
- 25 May 2017
- Published by Medip Academy in International Journal of Reproduction, Contraception, Obstetrics and Gynecology
- Vol. 6 (6) , 2618-2621
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for sarcomatosis from uterine adenosarcoma
Uterine adenosarcoma has poor prognosis and management of this disease is controversial. We describe a case of sarcomatosis secondary to recurrent uterine adenosarcoma who underwent cytoreductive surgery (CS) and hyperthermic intraoperative peritoneal chemotherapy (HIPEC). A 52 year-old female presented with perimenopausal menometrorrhagia. She underwent laparoscopic hysterectomy and bilateral salpingo-oopherectomy with pathology showing uterine adenosarcoma. She developed a pelvic recurrence 2 years later. A pelvic exenteration was then performed and within 8 months, she recurred. CS/HIPEC with Cisplatin was performed. Six weeks post-operatively, the patient was found to have recurrence again. This case describes the use of CS/HIPEC as a treatment modality for uterine adenosarcoma with sarcomatosis. Despite CS and HIPEC, the patient developed an aggressive recurrence within six weeks of her surgery date. We recommend a multidisciplinary approach to this disease with the recognition that CS/HIPEC may offer little benefit as a salvage therapy based on this case.
- 25 May 2017
- Published by Medip Academy in International Journal of Reproduction, Contraception, Obstetrics and Gynecology
- Vol. 6 (6) , 2618-2621
Open AccessCytoreductive surgery and hyperthermic intraperitoneal chemotherapy for sarcomatosis from uterine adenosarcoma
Uterine adenosarcoma has poor prognosis and management of this disease is controversial. We describe a case of sarcomatosis secondary to recurrent uterine adenosarcoma who underwent cytoreductive surgery (CS) and hyperthermic intraoperative peritoneal chemotherapy (HIPEC). A 52 year-old female presented with perimenopausal menometrorrhagia. She underwent laparoscopic hysterectomy and bilateral salpingo-oopherectomy with pathology showing uterine adenosarcoma. She developed a pelvic recurrence 2 years later. A pelvic exenteration was then performed and within 8 months, she recurred. CS/HIPEC with Cisplatin was performed. Six weeks post-operatively, the patient was found to have recurrence again. This case describes the use of CS/HIPEC as a treatment modality for uterine adenosarcoma with sarcomatosis. Despite CS and HIPEC, the patient developed an aggressive recurrence within six weeks of her surgery date. We recommend a multidisciplinary approach to this disease with the recognition that CS/HIPEC may offer little benefit as a salvage therapy based on this case.
- 19 November 2016
- Published by Springer Nature
- p. 383-387
Emergencies After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- 19 November 2016
- Published by Springer Nature
- p. 383-387
Emergencies After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- 1 April 2016
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 20 (4) , 688-692
Assessment of the Double-Staple Technique for Esophagoenteric Anastomosis in Gastric Cancer
- 1 April 2016
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 20 (4) , 688-692
Assessment of the Double-Staple Technique for Esophagoenteric Anastomosis in Gastric Cancer